

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) An article for delivering a drug and a nucleic acid, the article comprising:
a nanoparticle forming a micelle; having a first portion capable of associating
a nucleic acid associated with an exterior of the micelle; and a second portion capable of associating
a drug associated with an interior of the micelle.
2. (Cancelled)
3. (Original) An article as in claim 1 wherein the nanoparticle is capable of passing through a cell membrane.
4. (Original) An article as in claim 1 wherein the nucleic acid is DNA
5. (Original) An article as in claim 1 wherein the drug is a cancer drug
- 6-7. (Cancelled)
8. (Original) An article as in claim 1 wherein the nanoparticle is stable at a concentration of greater than 5 mg/L.
9. (Original) An article as in claim 1 wherein the nanoparticle is capable of crossing the blood/brain barrier.
10. (Original) A composition comprising an article of claim 1 and a pharmaceutically acceptable carrier.
11. (Original) An article as in claim 1 wherein the nanoparticle comprises a graft co-polymer having a backbone including tertiary amines, at least a portion of the tertiary amines quaternized and bound to a hydrophobic side chain.

12. (Original) An article as in claim 11 wherein the hydrophobic side chain comprises cholesterol.
13. (Original) An article as in claim 11 wherein the polymeric backbone comprises a copolymer of quaternized and non-quaternized tertiary ammonium groups.
14. (Original) An article as in claim 13 wherein the polymeric backbone further comprises an ester linkage.
15. (Original) An article as in claim 13 wherein the polymeric backbone comprises a polyester.
16. (Original) An article as in claim 13 wherein the polymeric backbone further comprises a polyether.
- 17-43. (Cancelled)
44. (Currently Amended) A kit comprising:
a container including an amphoteric polymeric nanoparticle forming a micelle;
a nucleic acid associated with an exterior of the micelle;
a drug associated with an interior of the micelle; and
instructions for administering the nanoparticle to a subject.
- 45-48. (Cancelled)
49. (New) An article as in claim 1, wherein the nanoparticle comprises a polymeric compound.
50. (New) An article as in claim 49, wherein the polymeric compound is an amphiphilic copolymer.

51. (New) An article as in claim 50, wherein the amphiphilic co-polymer is a cationic amphiphilic co-polymer.
52. (New) An article as in claim 1 wherein the drug is not covalently or ionically bound to the nanoparticle.
53. (New) An article as in claim 1 wherein the drug is physically contained by the nanoparticle.